Merck’s net income for Q1 2024 increases by 69% to $4.76bn

2024-04-26
Pharmaceutical Technology
疫苗财报
MSD expects sales for full-year 2024 to be in the range of $63.1bn to $64.3bn. Credit: Michael Vi via Shutterstock.
MSDck & Co Inc (MSD) has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in the first quarter (Q1) of 2024, a 69% rise from $2.82bn in the first quarter of the previous year.
Merck & Co Inc pMSDormance reflects the company’s robust growth in key areas such as oncology and vaccines.
Sales for the first quarter of 2024 also saw an uptick, climbing by 9% to $15.77bn compared to $14.48bn in the same period of 2023.
The growth in sales was particularly notable in the oncology segment, where Keytruda, MSD’s cancer drug, experienced a 20% increase in sales to $6.9bn.
When adjusted for foreign exchange impacts, the sales growth for Keytruda waKeytrudaore proncancer at 24%.
See Also:Keytruda
AstraZeneca posts $2.18bn profit after tax in Q1 2024
AstraZeneca €300m investment at new German research centre
The company’s vaccine portfolio also contributed to the positive financial results, with Gardasil/Gardasil 9 sales growing by 14% to $2.2bn. Excluding the foreign exchange impact, the sales growth for these vaccines was 17%.
Merckhair and CEO Robert Davis said: “Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximising the impact of our broad commercial portfolio for the benefit of patients.
“We drove strong growth across key therapeutic areas, executed strategic business development, and in the US, we are now launching Winrevair, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realising them.”
Looking ahead, MSD has updated its full-year 2024 sales forecast. The company expects salGardasil Gardasilange of $63.1bn to $64.3bn.
MSDs projection includes a negative imMerckfrom foreign exchange of nearly 3% at mid-April 2024 exchange rates.
Before this development, MSD announced plans to invest more than €300m ($320.8m) in a new Life Science Research Center at its globaWinrevairrters in Darmstadt, Germany.pulmonary arterial hypertension
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。